(March 25, 2026, Beijing) — Today, the 2026 Zhongguancun Forum Annual Conference, themed “Deep Integration of Technological Innovation and Industrial Innovation,” grandly opened. As an innovative company dedicated to the field of neurointervention, AccuMedical presented its comprehensive neurointervention portfolio at the permanent exhibition. This marks the third consecutive year that AccuMedical has been invited to participate. Over the past three years, the company has forged ahead with determination, evolving from a rising technology player with a single flagship product into an industry pioneer offering comprehensive solutions that cover both hemorrhagic and ischemic stroke, as well as access systems for cerebrovascular interventions. Leveraging its strong foundation in original innovation and upholding its commitment to “true innovation for real-world application,” AccuMedical is driving transformation through a dual-engine strategy: enabling comprehensive procedural innovation and continuously developing blockbuster products. The company is becoming a key force in propelling China’s high-end medical devices onto the global stage.
Lv Yiran, Founder and CEO of AccuMedical, stated: “Guided by the national strategies of building a ‘Healthy China’ and fostering ‘new quality productive forces,’ China’s medical device industry is achieving breakthroughs through foundational technological innovation. As a primary driver of innovation, enterprises must take on the responsibility of deeply integrating the innovation chain with the industrial chain. AccuMedical has consistently adhered to deep ‘clinician-engineer collaboration,’ transforming clinical pain points into engineering starting points for product development, and using the improvement of patients’ quality of life as the ultimate benchmark for innovation. Through the Zhongguancun Forum, we will continue to advance from ‘domestic substitution’ to ‘global leadership,’ supporting the development of an accessible cerebrovascular disease diagnosis and treatment system with high-quality original innovations, while establishing a global benchmark for China’s ‘new quality productive forces.’”
(AccuMedical’s booth is located in the High-End Medical Device Exhibition Area of the Zhongguancun Forum permanent exhibition)
Highlights of the AccuMedical Booth:
When micron-level intelligent manufacturing meets life sciences, innovation is redefining the upper limits of cerebrovascular disease treatment. Over the past three years, the Zhongguancun Forum has witnessed AccuMedical’s leap from single-product breakthroughs to comprehensive technological innovation. At this year’s exhibition, the debut of its “comprehensive neurointervention portfolio” includes solutions for hemorrhagic stroke, ischemic stroke, and access products. With a high-quality portfolio of original innovations, AccuMedical is empowering procedural innovation and transformation across the board:
Hemorrhagic Stroke – Highly Effective Solutions: For the treatment of intracranial aneurysms, often referred to as “time bombs,” AccuMedical showcased its highly anticipated Lattice® series Flow Diverters. According to the latest real-world study presented at the 2026 International Stroke Conference (ISC) of the American Stroke Association (ASA), Lattice®—featuring its proprietary MIROR surface modification technology and self-expanding mechanical balloon delivery system—maintains excellent complete occlusion rates while significantly reducing in-stent stenosis (ISS) to 1.8%,a rate far below the 14.5% reported for conventional international devices. These authoritative clinical data demonstrate the substantial benefits of original innovation for patient outcomes and mark AccuMedical’s transition from “substitution” to “leadership,” with key performance metrics now surpassing international brands.
Ischemic Stroke – Rapid Recanalization of the Life Pathway: In acute ischemic stroke rescue, “time is life,” and efficient, safe thrombectomy tools are critical. AccuMedical presented a suite of thrombectomy products, including the Grism® Stent Retriever with Dual Capture Tripods, Attractor® Aspiration Catheter, Cosine45 Micro Intermediate Catheter, and Sine21 Microcatheter. This powerful combination enables broader clinical applications. Among them, Grism® features a unique Stent Retriever with Dual Capture Tripods that includes a distal capture tripod with no tip, specialized flower-shaped clot trapping cells, and fully visible dual capture tripods, delivering outstanding clot capture and anti-embolization performance. This design significantly reduces procedural complexity and shortens critical rescue time, ensuring rapid and effective revascularization for patients.
Full-Scenario Access Device Support: Precise access to the lesion is fundamental to the success of neurointerventional procedures. In addition to the Sine® microcatheter series and Cosine® distal access catheter series, AccuMedical highlighted its Paracurve® Radial Access Guiding Catheter, which leads the trend in minimally invasive approaches. Compared with traditional femoral access, the radial approach offers a shorter access path, significantly reducing procedure time and securing valuable golden rescue windows for patients. It is also less invasive and eliminates the need for prolonged bed rest, greatly improving postoperative experience.
(AccuMedical Neurointervention Product Portfolio)
AccuMedical implements technological self-reliance and strength across every stage of R&D. Addressing key clinical challenges—such as the heavy reliance on physician experience in neurointervention and the steep learning curve at primary care levels—the company continues to achieve breakthroughs in core underlying technologies, significantly lowering procedural barriers and accelerating the accessibility of advanced medical technologies at the grassroots level. From breaking away from the traditional path of “imitation and following” in domestic substitution to exporting China-originated solutions globally, AccuMedical is building an ever-evolving full-stack product portfolio, contributing indispensable Chinese strength to the global advancement of cerebrovascular disease diagnosis and treatment.